This abstract focuses on the development of an imaging assay based on multiparametric MRI and sodium (23Na) MRI to discriminate between low- and high-grade prostate cancer (PCa) lesions, using Gleason grade defined by whole-mount histopathology as the gold standard and PET targeting the prostate-specific membrane antigen (PSMA) as a validation. Data from the first patient (Gleason score 7) demonstrates that PSMA-PET may be superior in detecting PCa lesions in the transition zone and distant metastases while the sensitivity of the current 23Na radiofrequency system in this study is limited to lesions in the peripheral zone of the prostate.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords